TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis: The OPTIMIZE Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial
Brief Summary: The purpose of this trial is to compare the effects of treatment with tobramycin solution for inhalation (TIS) with and without azithromycin in people with cystic fibrosis (CF) age 6 months to 18 years who have early isolation of Pseudomonas aeruginosa (Pa) from a respiratory culture. Specimens of blood and sputum or throat swabs will be taken during the study along with pulmonary function testing. Participants will receive initial treatment with TIS followed additional treatment with TIS if quarterly respiratory cultures are positive for Pa in addition to either azithromycin or placebo for 18 months.


Options:
A: Arm Label: Observational; Type: N/A; Interventions: N/A
B: Arm Label: azithromycin and TIS; Type: ACTIVE_COMPARATOR; Interventions: Drug: azithromycin, Drug: Tobramycin solution for inhalation | Arm Label: placebo and TIS; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo, Drug: Tobramycin solution for inhalation | Intervention Type: DRUG; Name: azithromycin; Assigned to Arm(s): azithromycin and TIS | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo and TIS | Intervention Type: DRUG; Name: Tobramycin solution for inhalation; Assigned to Arm(s): azithromycin and TIS, placebo and TIS
C: Arm Label: TOBI (tobramycin inhaled solution)/Placebo; Type: EXPERIMENTAL; Interventions: Drug: TOBI, Drug: Placebo | Arm Label: Placebo/TOBI; Type: PLACEBO_COMPARATOR; Interventions: Drug: TOBI, Drug: Placebo | Intervention Type: DRUG; Name: TOBI; Assigned to Arm(s): Placebo/TOBI, TOBI (tobramycin inhaled solution)/Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo/TOBI, TOBI (tobramycin inhaled solution)/Placebo
D: Arm Label: Placebo (pooled two times a day [BID]/three times a day [TID]); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo two times a day (BID)/three times a day (TID) | Arm Label: AZLI (pooled two times a day [BID]/three times a day [TID]); Type: EXPERIMENTAL; Interventions: Drug: AZLI 75 mg two times a day (BID)/three times a day (TID) | Intervention Type: DRUG; Name: AZLI 75 mg two times a day (BID)/three times a day (TID); Assigned to Arm(s): AZLI (pooled two times a day [BID]/three times a day [TID]) | Intervention Type: DRUG; Name: Placebo two times a day (BID)/three times a day (TID); Assigned to Arm(s): Placebo (pooled two times a day [BID]/three times a day [TID])

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 48 Weeks Study of Three Different Dose Regimens of BI 655066 Administered Subcutaneously in Patients With Moderate to Severe Chronic Plaque Psoriasis (Randomised, Dose-ranging, Active-comparator-controlled (Ustekinumab), Double-blind Within Dose Groups of BI 655066)
Brief Summary: The overall purpose of this trial is to assess clinical efficacy and safety of different subcutaneous doses of BI 655066 in adult patients with chronic plaque psoriasis in order to select doses for further clinical trials.


Options:
A: Arm Label: Cohort 1; Type: EXPERIMENTAL; Interventions: Drug: (CP-6890,550) Tofacitinib, Drug: Placebo | Arm Label: Cohort 2; Type: EXPERIMENTAL; Interventions: Drug: (CP-690,550) Tofacitinib, Drug: Placebo | Intervention Type: DRUG; Name: (CP-6890,550) Tofacitinib; Assigned to Arm(s): Cohort 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1 | Intervention Type: DRUG; Name: (CP-690,550) Tofacitinib; Assigned to Arm(s): Cohort 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 2
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: BI 655066 | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: BI 655066 | Arm Label: Arm 3; Type: EXPERIMENTAL; Interventions: Drug: BI 655066 | Arm Label: Arm 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ustekinumab | Intervention Type: DRUG; Name: BI 655066; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: BI 655066; Assigned to Arm(s): Arm 3 | Intervention Type: DRUG; Name: Ustekinumab; Assigned to Arm(s): Arm 4 | Intervention Type: DRUG; Name: BI 655066; Assigned to Arm(s): Arm 1
C: Arm Label: Secukinumab 300 mg; Type: EXPERIMENTAL; Interventions: Biological: Secukinumab | Arm Label: Narrow-band ultraviolet B (nb-UVB); Type: ACTIVE_COMPARATOR; Interventions: Radiation: nb-UVB | Intervention Type: BIOLOGICAL; Name: Secukinumab; Assigned to Arm(s): Secukinumab 300 mg | Intervention Type: RADIATION; Name: nb-UVB; Assigned to Arm(s): Narrow-band ultraviolet B (nb-UVB)
D: Arm Label: Tildrakizumab 200 mg; Type: EXPERIMENTAL; Interventions: Drug: Tildrakizumab 200 mg, Drug: Matching Placebo | Arm Label: Tildrakizumab 100 mg; Type: EXPERIMENTAL; Interventions: Drug: Tildrakizumab 100 mg, Drug: Matching Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Tildrakizumab 200 mg, Drug: Tildrakizumab 100 mg, Drug: Matching Placebo | Intervention Type: DRUG; Name: Tildrakizumab 200 mg; Assigned to Arm(s): Placebo, Tildrakizumab 200 mg | Intervention Type: DRUG; Name: Tildrakizumab 100 mg; Assigned to Arm(s): Placebo, Tildrakizumab 100 mg | Intervention Type: DRUG; Name: Matching Placebo; Assigned to Arm(s): Placebo, Tildrakizumab 100 mg, Tildrakizumab 200 mg

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 48 Weeks Study of Three Different Dose Regimens of BI 655066 Administered Subcutaneously in Patients With Moderate to Severe Chronic Plaque Psoriasis (Randomised, Dose-ranging, Active-comparator-controlled (Ustekinumab), Double-blind Within Dose Groups of BI 655066)
Brief Summary: The overall purpose of this trial is to assess clinical efficacy and safety of different subcutaneous doses of BI 655066 in adult patients with chronic plaque psoriasis in order to select doses for further clinical trials.


Options:
A: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: etanercept | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: etanercept, Drug: Placebo | Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): B | Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): B
B: Arm Label: Active Treatment (10 mg) BID / Placebo BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Active Treatment (10 mg) BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Active Treatment (5 mg) BID / Placebo BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Active Treatment (5 mg) BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Active Treatment (10 mg) BID / Placebo BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Active Treatment (10 mg) BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Active Treatment (5 mg) BID / Placebo BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Active Treatment (5 mg) BID
C: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: BI 655066 | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: BI 655066 | Arm Label: Arm 3; Type: EXPERIMENTAL; Interventions: Drug: BI 655066 | Arm Label: Arm 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ustekinumab | Intervention Type: DRUG; Name: BI 655066; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: BI 655066; Assigned to Arm(s): Arm 3 | Intervention Type: DRUG; Name: Ustekinumab; Assigned to Arm(s): Arm 4 | Intervention Type: DRUG; Name: BI 655066; Assigned to Arm(s): Arm 1
D: Arm Label: Therapeutic drug monitoring; Type: EXPERIMENTAL; Interventions: Other: Therapeutic drug monitoring | Arm Label: Standard care; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard care | Intervention Type: OTHER; Name: Therapeutic drug monitoring; Assigned to Arm(s): Therapeutic drug monitoring | Intervention Type: OTHER; Name: Standard care; Assigned to Arm(s): Standard care

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The CHOICES/OPCIONES Project: Improving Colon Cancer Screening for Diverse Populations
Brief Summary: This study is a multi-site randomized, controlled trial testing the effect of a combined intervention that includes a colorectal cancer (CRC) screening decision aid plus patient navigation in a diverse, primary care patient population in clinical sites in North Carolina and New Mexico.

Our primary aim is to determine the effect of the intervention on CRC screening completion six months after the index visit among all enrolled participants and among Latinos. Secondarily, we will determine how this intervention affects screening-related knowledge, self-efficacy, intent, and clinical communication, and examine whether these factors mediate the effect of the intervention on screening test completion. Lastly, we will explore whether insurance status, ethnicity, and patient language preference moderate the effect of the intervention on screening.


Options:
A: Arm Label: Salud al Día; Type: EXPERIMENTAL; Interventions: Behavioral: Salud al Día | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Salud al Día; Assigned to Arm(s): Salud al Día
B: Arm Label: Community Health Worker Model; Type: EXPERIMENTAL; Interventions: Behavioral: CARIÑO Project | Arm Label: Enhanced Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Enhanced Usual Care | Intervention Type: BEHAVIORAL; Name: CARIÑO Project; Assigned to Arm(s): Community Health Worker Model | Intervention Type: BEHAVIORAL; Name: Enhanced Usual Care; Assigned to Arm(s): Enhanced Usual Care
C: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: Decision aid and navigation | Intervention Type: BEHAVIORAL; Name: Decision aid and navigation; Assigned to Arm(s): Intervention group
D: Arm Label: PREPARE intervention; Type: EXPERIMENTAL; Interventions: Behavioral: PREPARE Intervention | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: PREPARE Intervention; Assigned to Arm(s): PREPARE intervention

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pulsed Oral Sirolimus in Autosomal Dominant Polycystic Kidney Disease - The Vienna RAP Study
Brief Summary: Sirolimus (SIR) has lead to a reduction of overall kidney size, a decrease in cyst density and general tubular cell proliferation in animal models, and to a reduction of the increase in creatinine and blood urea nitrogen by 34 and 39 percent respectively, as well as a reduction of cyst proliferation, expressed by a 30 percent reduction of overall kidney enlargement, a reduction in general cyst volume, and a reduction of the cyst volume density in the renal cortex in humans.

However, despite promising data from animal- and in vivo studies, most mammalian target of rapamycin inhibitor (mTOR-I) studies in patients with autosomal-dominant polycystic kidney disease (ADPKD) produced only subtle if any clinically relevant effects on cyst growth and the preservation of renal function.

In this study we will investigate if pulsed administration of SIR in a fixed weekly oral dose of 3 mg over 24 months compared to placebo significantly reduces cyst growth and preserves excretory renal function in patients with ADPKD and an estimated glomerular filtration (eGFR) rate below 60 mL/min per 1.73m2.


Options:
A: Arm Label: Tolvaptan 45/15 mg/day orally for up to 4 years; Type: EXPERIMENTAL; Interventions: Drug: Tolvaptan | Arm Label: Tolvaptan 60/30 mg/day orally for up to 4 years; Type: EXPERIMENTAL; Interventions: Drug: Tolvaptan | Intervention Type: DRUG; Name: Tolvaptan; Assigned to Arm(s): Tolvaptan 45/15 mg/day orally for up to 4 years, Tolvaptan 60/30 mg/day orally for up to 4 years
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: OPC-41061 | Intervention Type: DRUG; Name: OPC-41061; Assigned to Arm(s): 1
C: Arm Label: Sirolimus; Type: EXPERIMENTAL; Interventions: Drug: Sirolimus | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Sirolimus; Assigned to Arm(s): Sirolimus | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Everolimus + octreotide LAR; Type: ACTIVE_COMPARATOR; Interventions: Drug: Everolimus, Drug: Octreotide LAR | Arm Label: Octreotide LAR; Type: ACTIVE_COMPARATOR; Interventions: Drug: Octreotide LAR | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Everolimus + octreotide LAR | Intervention Type: DRUG; Name: Octreotide LAR; Assigned to Arm(s): Everolimus + octreotide LAR, Octreotide LAR

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Complementary Treatments for Smoking Cessation
Brief Summary: The purpose of this pilot study is to examine the feasibility and preliminary efficacy of a quit-smoking program that combines behavioral therapy with either yoga, or a health \& wellness program that serves as a contact control.


Options:
A: Arm Label: Yoga; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Behavioral Therapy for Smoking Cessation, Behavioral: Yoga | Arm Label: Health & Wellness; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive Behavioral Therapy for Smoking Cessation, Behavioral: Health & Wellness | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy for Smoking Cessation; Assigned to Arm(s): Health & Wellness, Yoga | Intervention Type: BEHAVIORAL; Name: Yoga; Assigned to Arm(s): Yoga | Intervention Type: BEHAVIORAL; Name: Health & Wellness; Assigned to Arm(s): Health & Wellness
B: Arm Label: Experimental; Type: EXPERIMENTAL; Interventions: Behavioral: Smartphone-delivered Intervention (SmartQuit) | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: : Smartphone-delivered Intervention (Standard of care app) | Intervention Type: BEHAVIORAL; Name: Smartphone-delivered Intervention (SmartQuit); Assigned to Arm(s): Experimental | Intervention Type: BEHAVIORAL; Name: : Smartphone-delivered Intervention (Standard of care app); Assigned to Arm(s): Control
C: Arm Label: Experimental App; Type: EXPERIMENTAL; Interventions: Behavioral: Experimental App | Arm Label: Active comparator app; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Active Comparator App | Intervention Type: BEHAVIORAL; Name: Experimental App; Assigned to Arm(s): Experimental App | Intervention Type: BEHAVIORAL; Name: Active Comparator App; Assigned to Arm(s): Active comparator app
D: Arm Label: Quit Line Only; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Quit Line Only | Arm Label: Quit Line plus MTS; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Quit Line plus MTS | Intervention Type: BEHAVIORAL; Name: Quit Line plus MTS; Assigned to Arm(s): Quit Line plus MTS | Intervention Type: BEHAVIORAL; Name: Quit Line Only; Assigned to Arm(s): Quit Line Only

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: the Effect of Low-Concentration Atropine Combined With Auricular Acupoint Stimulation in Myopia Control
Brief Summary: To compare the effect of myopia control between patients treated with low-concentration atropine eye drops combined with auricular acupoint stimulation and those treated with atropine alone.


Options:
A: Arm Label: auricular acupoint stimulation; Type: EXPERIMENTAL; Interventions: Drug: Atropine, Device: auricular acupoint stimulation | Arm Label: Atropine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atropine | Intervention Type: DRUG; Name: Atropine; Assigned to Arm(s): Atropine, auricular acupoint stimulation | Intervention Type: DEVICE; Name: auricular acupoint stimulation; Assigned to Arm(s): auricular acupoint stimulation
B: Intervention Type: DRUG; Name: Atropine Eye drops; Assigned to Arm(s): N/A
C: Arm Label: Contact Lens; Type: EXPERIMENTAL; Interventions: Device: Soft contact lenses | Arm Label: Spectacle; Type: ACTIVE_COMPARATOR; Interventions: Device: Spectacle | Intervention Type: DEVICE; Name: Soft contact lenses; Assigned to Arm(s): Contact Lens | Intervention Type: DEVICE; Name: Spectacle; Assigned to Arm(s): Spectacle
D: Arm Label: orthokeratology lenses; Type: EXPERIMENTAL; Interventions: Device: orthokeratology lenses | Arm Label: single-vision spectacle lenses; Type: OTHER; Interventions: Device: single-vision spectacle lenses | Intervention Type: DEVICE; Name: orthokeratology lenses; Assigned to Arm(s): orthokeratology lenses | Intervention Type: DEVICE; Name: single-vision spectacle lenses; Assigned to Arm(s): single-vision spectacle lenses

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: the Effect of Low-Concentration Atropine Combined With Auricular Acupoint Stimulation in Myopia Control
Brief Summary: To compare the effect of myopia control between patients treated with low-concentration atropine eye drops combined with auricular acupoint stimulation and those treated with atropine alone.


Options:
A: Arm Label: omafilcon A; Type: EXPERIMENTAL; Interventions: Device: omafilcon A | Arm Label: Spectacle Group; Type: ACTIVE_COMPARATOR; Interventions: Device: Spectacle | Intervention Type: DEVICE; Name: omafilcon A; Assigned to Arm(s): omafilcon A | Intervention Type: DEVICE; Name: Spectacle; Assigned to Arm(s): Spectacle Group
B: Arm Label: Progressive Addition Lenses (PALs); Type: EXPERIMENTAL; Interventions: Other: Progressive Addition Lenses | Arm Label: Single Vision Lenses; Type: ACTIVE_COMPARATOR; Interventions: Other: single vision lenses | Intervention Type: OTHER; Name: Progressive Addition Lenses; Assigned to Arm(s): Progressive Addition Lenses (PALs) | Intervention Type: OTHER; Name: single vision lenses; Assigned to Arm(s): Single Vision Lenses
C: Arm Label: intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: increasing time spent outdoors | Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: increasing time spent outdoors; Assigned to Arm(s): intervention group
D: Arm Label: auricular acupoint stimulation; Type: EXPERIMENTAL; Interventions: Drug: Atropine, Device: auricular acupoint stimulation | Arm Label: Atropine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atropine | Intervention Type: DRUG; Name: Atropine; Assigned to Arm(s): Atropine, auricular acupoint stimulation | Intervention Type: DEVICE; Name: auricular acupoint stimulation; Assigned to Arm(s): auricular acupoint stimulation

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase Ib and Randomised Phase II Trial of Pazopanib With or Without Fosbretabulin in Advanced Recurrent Ovarian Cancer
Brief Summary: The first part of this study is to find the recommended dosages of a combination of two drugs: pazopanib and fosbretabulin, which will be given to female patients with relapsed ovarian cancer.

The second part of the study involves comparing the recommended dose of pazopanib and fosbretabulin in combination against pazopanib alone in female patients with relapsed ovarian cancer to determine whether the combination is more beneficial that pazopanib on it's own.


Options:
A: Arm Label: Phase Ib/II: Fosbretabulin & Pazopanib; Type: EXPERIMENTAL; Interventions: Drug: Pazopanib, Drug: Fosbretabulin | Arm Label: Phase II: Pazopanib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pazopanib | Intervention Type: DRUG; Name: Pazopanib; Assigned to Arm(s): Phase II: Pazopanib, Phase Ib/II: Fosbretabulin & Pazopanib | Intervention Type: DRUG; Name: Fosbretabulin; Assigned to Arm(s): Phase Ib/II: Fosbretabulin & Pazopanib
B: Arm Label: Telcyta + Liposomal Doxorubicin; Type: EXPERIMENTAL; Interventions: Drug: Telcyta, Drug: Liposomal Doxorubicin | Arm Label: Liposomal Doxorubicin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Liposomal Doxorubicin | Intervention Type: DRUG; Name: Telcyta; Assigned to Arm(s): Telcyta + Liposomal Doxorubicin | Intervention Type: DRUG; Name: Liposomal Doxorubicin; Assigned to Arm(s): Liposomal Doxorubicin, Telcyta + Liposomal Doxorubicin
C: Arm Label: Ixabepilone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ixabepilone | Arm Label: Ixabepilone + Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Ixabepilone, Drug: Bevacizumab | Intervention Type: DRUG; Name: Ixabepilone; Assigned to Arm(s): Ixabepilone, Ixabepilone + Bevacizumab | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Ixabepilone + Bevacizumab
D: Arm Label: Olaparib; Type: EXPERIMENTAL; Interventions: Drug: Olaparib | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Olaparib; Assigned to Arm(s): Olaparib | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Hormones and Physical Exercise (HOPE) Study
Brief Summary: The investigators propose to examine 121 postmenopausal women diagnosed with hormone-receptor positive breast cancer who have been taking aromatase inhibitors (AI) for at least 6 months and are experiencing at least mild arthralgia originating during AI treatment, the yearlong effect of exercise vs. attention control (health education), and on toxic side effects of AI.


Options:
A: Arm Label: Web-based, Stage-matched Exercise and Diet Planning program; Type: EXPERIMENTAL; Interventions: Behavioral: Web-based Health Planner on diet and exercise | Arm Label: Non-tailored booklet on exercise and diet; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Non-tailored booklet on exercise and diet | Intervention Type: BEHAVIORAL; Name: Web-based Health Planner on diet and exercise; Assigned to Arm(s): Web-based, Stage-matched Exercise and Diet Planning program | Intervention Type: BEHAVIORAL; Name: Non-tailored booklet on exercise and diet; Assigned to Arm(s): Non-tailored booklet on exercise and diet
B: Arm Label: Exercise Counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Physical activity counseling | Arm Label: Contact Control; Type: PLACEBO_COMPARATOR; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Physical activity counseling; Assigned to Arm(s): Exercise Counseling
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Physical exercise | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Physical exercise | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: Physical exercise | Intervention Type: BEHAVIORAL; Name: Physical exercise; Assigned to Arm(s): 1, 2, 3
D: Arm Label: Exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise | Arm Label: Attention Control (Health Education); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Attention Control (Health Education) | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Exercise | Intervention Type: BEHAVIORAL; Name: Attention Control (Health Education); Assigned to Arm(s): Attention Control (Health Education)

Answer: D